Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

211.54 +0.96 (+0.46%)
Streaming Delayed Price Updated: 1:40 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
From Natera, Inc.
Via Business Wire
News headline image
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
From Natera, Inc.
Via Business Wire
News headline image
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
From Natera, Inc.
Via Business Wire
News headline image
Natera Submits First PMA Module to the FDA for Signatera™
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Senior Leadership Appointments
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Pricing of $250 Million Follow-On Offering
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches Proposed Follow-On Offering
From Natera, Inc.
Via Business Wire
News headline image
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
News headline image
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Second Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
From Natera, Inc.
Via Business Wire
News headline image
Natera Files Patent Infringement Suit Against NeoGenomics
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Second Quarter 2023 Results on August 3rd
From Natera, Inc.
Via Business Wire
News headline image
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
From Natera, Inc.
Via Business Wire
News headline image
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
From Natera, Inc.
Via Business Wire
News headline image
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
From Natera, Inc.
Via Business Wire
News headline image
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports First Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces First Quarter 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Commercial Payor Coverage for Signatera™
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.